Seeking Alpha
View as an RSS Feed

Spencer Osborne  

View Spencer Osborne's Comments BY TICKER:
Latest  |  Highest rated
  • Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away [View article]
    Counter....

    Not the way you want to spin it. You want to compare Vivus net revenue vs. the share of revenue that arena and orexigen get.n I have shown you this is wrong, but you are so obsessed with trying to be a wise guy that you can not see things straight.

    If smart think we're gas, and you were a flea, you would not have enough gas to fill up a mini bike and ride around the interior of a Cheerio.
    Jun 2, 2015. 03:29 PM | 1 Like Like |Link to Comment
  • Vivus-Qsymia Sales Post Modest Gain - Slow And Steady Does Not Win The Race [View article]
    Counter...

    Qsymia is trudging along in first gear when it needs to be in 5th gear. Deal with it
    Jun 2, 2015. 03:26 PM | 1 Like Like |Link to Comment
  • Vivus-Qsymia Sales Post Modest Gain - Slow And Steady Does Not Win The Race [View article]
    Counter...

    Do a little math and stop stalking. Partnership is worth about $100 million up front and having someone else pay for marketing. It is pretty important. Vivus management has stated so about 3.4567 million times over the last 4 years.
    Jun 2, 2015. 03:26 PM | 1 Like Like |Link to Comment
  • Arena-Belviq Sales Still Flat - Drug Staves Off Competition For Another Week [View article]
    J.

    Depends on what you look at for a trend. In Q2 Belviq is trending down and the other two up
    Jun 2, 2015. 03:20 PM | 1 Like Like |Link to Comment
  • Arena-Belviq Sales Still Flat - Drug Staves Off Competition For Another Week [View article]
    Rod....Contrave down 2.5%. Belviq up 0.06% Qsymia up 1.5%.
    Jun 2, 2015. 03:19 PM | 1 Like Like |Link to Comment
  • Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away [View article]
    Trx....

    Yes, but you will see passionate Vivus and arena investors say that the wheels are falling off. Some people just love to spin things to a light that makes one spear better than the other. These three are essentially all about the same in terms of what they do. It baffles me that people carry such emotions.
    Jun 2, 2015. 02:45 PM | 2 Likes Like |Link to Comment
  • Arena-Belviq Sales Still Flat - Drug Staves Off Competition For Another Week [View article]
    Rod....

    The sector did okay this Memorial Day week this year, but the sales trajectories of all three this quarter are much lower than needed. Belviq has had the worst trajectory of the quarter.
    Jun 2, 2015. 02:41 PM | 1 Like Like |Link to Comment
  • Arena-Belviq Sales Still Flat - Drug Staves Off Competition For Another Week [View article]
    Rod....

    For what purpose? Sales this quarter are flat/down.
    Jun 2, 2015. 01:56 PM | 1 Like Like |Link to Comment
  • Arena-Belviq Sales Still Flat - Drug Staves Off Competition For Another Week [View article]
    Jriver....

    1. Look at the charts again

    2. Please look at what I have stated for the last 6 months
    Jun 2, 2015. 01:55 PM | 1 Like Like |Link to Comment
  • Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away [View article]
    Long...

    Be shocked for all of 1 week.
    Jun 2, 2015. 01:53 PM | 2 Likes Like |Link to Comment
  • Orexigen: Contrave Sales Dip, Passing Belviq Still A Few Weeks Away [View article]
    Counter....

    As stated to you over and over and over and over and over and over and over and over and over.....the bottom line is material. Revenue per rep is not.
    Jun 2, 2015. 01:50 PM | 2 Likes Like |Link to Comment
  • Vivus-Qsymia Sales Post Modest Gain - Slow And Steady Does Not Win The Race [View article]
    Counter....

    Still stalking...

    Of course, Contrave sold about 2,000 more scripts than Qsymia, but let's not let real numbers get in the way of your spin.
    Jun 2, 2015. 01:48 PM | 1 Like Like |Link to Comment
  • Arena: Belviq Sales Take Big Step Back - Advertising Needed [View article]
    If I may interject....

    You guys are arguing two different things.

    To Sedric's point, these drugs see an initial success in about half of the people. Most lose their weight in 12 to 16 weeks and then level off.

    About half are able to lose 25% in the first 12 weeks.

    One major issue here is that when people stop losing weight, they come off of the drug and then, of course, gain weight back.

    If one were to lose 5% and stay on the drug, they have a decent shot at keeping the weight off. The problem is that people want weight loss with these drugs and when a plateau is reached, they see the drug as having done the best it can do. People do not seem to be willing to pay in order to keep weight off.

    These drugs are all supposed to be taken in conjunction with a diet and exercise program. To many people think the pill needs to do all of the work.
    Jun 1, 2015. 08:34 AM | 1 Like Like |Link to Comment
  • Orexigen And Takeda In Chess Match [View article]
    Counter....

    Stop your stalking. You are a disingenuous person and your comment history proves that out. You need to find a life dude
    May 29, 2015. 06:24 PM | 2 Likes Like |Link to Comment
  • Orexigen And Takeda In Chess Match [View article]
    Counter....

    You remain a stalker and a disingenuous person.

    Qsymia is approaching 3 years on the market and is performing dismally against competition. With less money spent to market it and fewer reps than ever, what on earth.....no, what in the solar system,,,,,no, what in the universe makes you think that people will wake up one day and take the drug that is marginally more effective yet has the longest and most severe list of adverse events AND has a REMS program.

    Stop stalking and get a life
    May 29, 2015. 06:23 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
8,716 Comments
7,299 Likes